Neurology
Tetracosactrin
Brand: Synacthen Depot
PBAC's latest decision on Tetracosactrin: Recommended with restriction (2017). Considered for Hypsarrhythmia and/or infantile spasms.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
2017 → 2017
Eligible population
Patients with hypsarrhythmia and/or infantile spasms.
- Therapy area
- Neurology
- Line of therapy
- Not applicable
- Evidence base
- Other
- Economic model
- Not modelled
- ICER note
- Minor submission with no economic evaluation; no ICER calculated.
Similar precedents
Open on full dashboard →